RecruitingPhase 2NCT07680946

Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

Evaluating Safety and Efficacy of Ublituximab in Participants With Schizophrenia

Sponsor

TG Therapeutics, Inc.

Enrollment

60 participants

Start Date

Jul 3, 2026

Study Type

INTERVENTIONAL

Conditions

Schizophrenia

Summary

The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by positive and negative syndrome scale (PANSS) total score in participants with schizophrenia.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ublituximab for people with schizophrenia. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.